Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Pliant Therapeutics' stock plummeted, but Kevin Tang’s stake raises takeover hopes. Find out why PLRX stock’s cash reserves ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses, struggling Allakos is welcoming a $0.33 per share buyout offer with op | ...

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 ...

The New York City Economic Development Corporation (NYCEDC) announced that three new companies are coming to the Brooklyn ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin alphavbeta8 and ...

Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF ...

Pliant Therapeutics, Inc. has announced the adoption of a limited duration stockholder rights agreement aimed at protecting shareholder interests in light of recent stock accumulations.